ByTrending Posts
Can Merck’s $3 Billion Restructuring Drive Sustainable Growth…
About MerckMerck & Co., Inc. (MSD outside US & Canada) is a global biopharmaceutical company dedicated to innovating…
Is Bristol Myers Squibb’s $300M Immunology Venture with…
Key Highlights About Bristol-Myers SquibbBristol-Myers Squibb is a global biopharmaceutical leader focused on innovative medicines in oncology, immunology,…
How Is GSK’s Robust Q2 2025 Growth Powering…
Key Highlights Specialty Medicines Fuel Strong Market MomentumGSK’s specialty portfolio, notably in Respiratory, Immunology & Inflammation (+10%) and…
Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the…
Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…
Is Aptitude’s $9M BARDA Partnership and Metrix Filovirus…
Key Highlights BARDA Partnership Accelerates Filovirus Diagnostic InnovationAptitude’s second collaboration with BARDA brings $9 million in new federal…
Is Aidoc’s $150M Bet on CARE™ and aiOS™…
Key Highlights CARE™ Foundation Model Redefining Standards in Clinical AIAidoc’s CARE™ model—now backed by $150 million in new…
Pfizer Secures Exclusive Global Rights to 3SBio’s Bispecific…
Key Highlights A Bold Bet on BispecificsIn a significant expansion of its oncology pipeline, Pfizer has obtained exclusive…
Can AstraZeneca’s Imfinzi Redefine Gastric Cancer Treatment With…
Key Highlights A New Chapter for Immunotherapy in Early-Stage GI CancersAstraZeneca’s Imfinzi is poised to become the first…
Could GSK and Hengrui’s $12B Alliance Set a…
Key Highlights GSK Bets Big on Hengrui: A $12B Strategic Play Anchored in Respiratory InnovationIn a high-stakes bet…
Trending Posts
Latest Stories
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada)…
Can Eli Lilly’s 2025 Brand Launches and Label Expansions Redefine Leadership in Metabolic, Oncology, and Neuroscience Markets Beyond 2026?
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through…
Can Pfizer’s 2025 Brand Launches Across Vaccines, Oncology, and Specialty Care Reshape Its Growth Trajectory Beyond 2026?
Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a…
Gallery
